{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:26:20Z","timestamp":1794587180911,"version":"4.9.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Biliary tract cancer is a highly dangerous cancer that often results in a poor prognosis for patients, even with significant advancements in treatment options. Recent advancements in targeted therapies and immunotherapy have shown great potential in treating various cancers. This underscores the importance of conducting a detailed review and meta-analysis of these approaches specifically for biliary tract cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This meta-analysis included data from randomized clinical trials and cohort studies examining the use of immunotherapy and targeted therapies specifically as second-line treatments for patients diagnosed with biliary tract cancer. A comprehensive andsystematic literature search was conducted across prominent databases, including PubMed, Embase, Cochrane Library, and Web of Science, encompassing publications from the inception of these databases until August 31, 2024. Key outcome measures, such as objective response rate (ORR), DCR, progression-free survival, overall survival, and AEs, were meticulously extracted for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The findings of this meta-analysis revealed that the ORR across the included studies varied from 4% to 33%, with a combined ORR of 14% (95% confidence interval [CI]: 9%\u201319%). The pooled DCR was calculated at 68% (95% CI: 53%-77%). Median overall survival was reported as 10.75 months (95% CI: 8.23\u201313.27 months), while median progression-free survival was 4.39 months (95% CI: 2.73\u20136.04 months).<\/jats:p>\n                    <jats:p>In terms of AEs, most patients experienced only grade 1 to 2 events, indicating a generally favorable tolerance to treatment. The most commonly reported AEs included fatigue (44%, 95% CI: 31%\u201358%), hypertension (41%, 95% CI: 28%\u201355%), and nausea (23%, 95% CI: 18%\u201329%). Additionally, thrombocytopenia emerged as the most prevalent hematological toxicity, occurring in 31% of patients (95% CI: 23%\u201339%). Notably, the incidence of \u2265grade III AEs was very low, remaining below 14%. Among the most frequent severe AEs were hypertension and elevated aminotransferases, with incidences of 14% and 8%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This comprehensive meta-analysis highlights the potential role of targeted therapies and immunotherapy in the management of biliary tract cancer, demonstrating promising albeit moderate efficacy. These findings underscore the necessity for further research and clinical trials aimed at optimizing treatment protocols to enhance outcomes for patients afflicted with this challenging malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049290","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:00:20Z","timestamp":1782108020000},"page":"e49290","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of combination immunotherapy and targeted therapy as second-line and subsequent treatments for advanced biliary tract cancer: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Yiran","family":"Liao","sequence":"first","affiliation":[{"name":"Phase I Clinical Research Center, Chongqing University Cancer Hospital, Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chongqing University Cancer Hospital, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8175-3632","authenticated-orcid":false,"given":"Jiong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chongqing University Cancer Hospital, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261113","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer.","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"R2-20261113","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world.","volume":"70","author":"Asrani","year":"2019","journal-title":"J Hepatol"},{"key":"R3-20261113","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1634\/theoncologist.2018-0044","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF).","volume":"23","author":"Arkenau","year":"2018","journal-title":"Oncologist"},{"key":"R4-20261113","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.3390\/cancers13205074","article-title":"Quality of life and symptom management in advanced biliary tract cancers.","volume":"13","author":"Hunter","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R5-20261113","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R6-20261113","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"R7-20261113","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers.","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"R8-20261113","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC.","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R9-20261113","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"R10-20261113","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"R11-20261113","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.32548","article-title":"Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.","volume":"77","author":"Zhou","year":"2023","journal-title":"Hepatology"},{"key":"R12-20261113","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression.","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R13-20261113","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"R14-20261113","doi-asserted-by":"crossref","first-page":"103919","DOI":"10.1016\/j.esmoop.2024.103919","article-title":"Phase I\/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808\/NCCH1817, SNIPE).","volume":"9","author":"Ueno","year":"2024","journal-title":"ESMO Open"},{"key":"R15-20261113","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/ijc.34372","article-title":"Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: an open-label, single-arm, phase II clinical trial.","volume":"152","author":"Jin","year":"2023","journal-title":"Int J Cancer"},{"key":"R16-20261113","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1007\/s00262-023-03523-2","article-title":"Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.","volume":"72","author":"Chao","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"R17-20261113","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2021.11.012","article-title":"Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.","volume":"162","author":"Cousin","year":"2022","journal-title":"Eur J Cancer"},{"key":"R18-20261113","doi-asserted-by":"crossref","first-page":"646979","DOI":"10.3389\/fonc.2021.646979","article-title":"The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: a prospective clinical study.","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"R19-20261113","doi-asserted-by":"crossref","first-page":"e152670","DOI":"10.1172\/JCI152670","article-title":"Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.","volume":"131","author":"Yarchoan","year":"2021","journal-title":"J Clin Invest"},{"issue":"15_suppl","key":"R20-20261113","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1200\/JCO.2021.39.15_suppl.4080","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.","volume":"39","author":"Villanueva","year":"2021","journal-title":"J Clin Oncol"},{"key":"R21-20261113","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R22-20261113","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/cancers15010039","article-title":"Efficacy and safety of first-line targeted treatment and immunotherapy for patients with biliary tract cancer: a systematic review and meta-analysis.","volume":"15","author":"Yan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R23-20261113","doi-asserted-by":"crossref","first-page":"e41767","DOI":"10.1097\/MD.0000000000041767","article-title":"Eye acupuncture therapy for insomnia: a systematic review and meta-analysis.","volume":"104","author":"Wang","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"R24-20261113","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41416-018-0138-2","article-title":"A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin.","volume":"119","author":"Zheng","year":"2018","journal-title":"Br J Cancer"},{"key":"R25-20261113","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol"},{"key":"R26-20261113","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/ijms23020820","article-title":"Immunotherapy for biliary tract cancer in the era of precision medicine: current knowledge and future perspectives.","volume":"23","author":"Ciardiello","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R27-20261113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000513847","article-title":"Targeting HER2 in biliary tract carcinomas: challenges and opportunities.","volume":"44","author":"Koeberle","year":"2021","journal-title":"Oncol Res Treat"},{"key":"R28-20261113","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:00:18Z","timestamp":1794585618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":28,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049290","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2025-08-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}